AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	274.75M
Revenue (ttm)	198.51M
Net Income (ttm)	11.61M
Shares Out	104.87M
EPS (ttm)	0.10
PE Ratio	25.76
Forward PE	18.11
Dividend	0.02 (0.61%)
Ex-Dividend Date	Jun 19, 2024

Volume	25,425
Average Volume	10,797
Open	2.600
Previous Close	2.620
Day's Range	2.580 - 2.610
52-Week Range	2.370 - 3.420
Beta	0.34
RSI	48.66
Earnings Date	May 22, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharma...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 110
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2023, AFT Pharmaceuticals's revenue was 195.41 million, an increase of 24.75% compared to the previous year's 156.64 million. Earnings were 15.61 million, an increase of 46.51%.